HK1220142A1 - 抗體 - Google Patents

抗體

Info

Publication number: HK1220142A1
Authority: HK; Hong Kong
Prior art keywords: antibodies
Prior art date: 2013-08-30

Application number

HK16108335.9A

Other languages

English (en)

Inventor

Graham Craggs

Karine Jeannine Madeleine Herv

Diane Marshall

Original Assignee

Ucb Biopharma Sprl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-30

Filing date

2016-07-15

Publication date

2017-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1220142(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-07-15 Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl

2017-04-28 Publication of HK1220142A1 publication Critical patent/HK1220142A1/zh

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

HK16108335.9A 2013-08-30 2016-07-15 抗體 HK1220142A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1315487.7A GB201315487D0 (en)	2013-08-30	2013-08-30	Antibodies
PCT/EP2014/068050 WO2015028455A1 (en)	2013-08-30	2014-08-26	Antibodies

Publications (1)

Publication Number	Publication Date
HK1220142A1 true HK1220142A1 (zh)	2017-04-28

Family

ID=49397073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK16108335.9A HK1220142A1 (zh)	2013-08-30	2016-07-15	抗體

Country Status (39)

Country	Link
US (2)	US9908939B2 (zh)
EP (3)	EP3038643B1 (zh)
JP (3)	JP6632075B2 (zh)
KR (1)	KR102303130B1 (zh)
CN (2)	CN112321711A (zh)
AR (1)	AR097464A1 (zh)
AU (1)	AU2014314304B2 (zh)
BR (1)	BR112016004324B1 (zh)
CA (1)	CA2922240C (zh)
CL (1)	CL2016000438A1 (zh)
CY (1)	CY1121964T1 (zh)
DK (2)	DK3549599T3 (zh)
EA (1)	EA036255B1 (zh)
ES (2)	ES2965207T3 (zh)
FI (1)	FI3549599T3 (zh)
GB (1)	GB201315487D0 (zh)
HK (1)	HK1220142A1 (zh)
HR (2)	HRP20231264T1 (zh)
HU (2)	HUE064437T2 (zh)
IL (1)	IL244043B (zh)
LT (2)	LT3038643T (zh)
MA (2)	MA44922B1 (zh)
MX (1)	MX2016002166A (zh)
MY (1)	MY172484A (zh)
NZ (1)	NZ717399A (zh)
PE (2)	PE20160528A1 (zh)
PH (1)	PH12016500275A1 (zh)
PL (2)	PL3038643T3 (zh)
PT (2)	PT3549599T (zh)
RS (2)	RS64784B1 (zh)
SG (1)	SG11201601151PA (zh)
SI (2)	SI3038643T1 (zh)
TN (1)	TN2016000067A1 (zh)
TR (1)	TR201909478T4 (zh)
TW (1)	TWI531582B (zh)
UA (1)	UA118354C2 (zh)
UY (1)	UY35718A (zh)
WO (1)	WO2015028455A1 (zh)
ZA (1)	ZA201601437B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201315487D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
JP6851322B2 (ja) *	2015-05-27	2021-03-31	ユーシービーバイオファルマエスアールエル	神経疾患を治療する方法
JP2018516933A (ja) *	2015-06-02	2018-06-28	ジェネンテック，インコーポレイテッド	抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
WO2017220988A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Multispecific antibodies for immuno-oncology
WO2018183366A1 (en)	2017-03-28	2018-10-04	Syndax Pharmaceuticals, Inc.	Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
JP2020520943A (ja) *	2017-05-19	2020-07-16	シンダックスファーマシューティカルズ，インコーポレイテッド	併用療法
GB201803226D0 (en)	2018-02-28	2018-04-11	Ultrahuman Twelve Ltd	CSF1R Binding agents
CN109096397B (zh) *	2018-07-18	2019-04-16	博奥信生物技术（南京）有限公司	一种抗人csf-1r单克隆抗体及应用
CN108948198B (zh) *	2018-07-18	2020-09-01	博奥信生物技术（南京）有限公司	抗人csf-1r单克隆抗体及其应用
TWI733274B (zh) *	2018-12-13	2021-07-11	財團法人生物技術開發中心	抗人類csf-1r抗體及其用途
CN113939539A (zh) *	2019-05-15	2022-01-14	博奥信生物技术（南京）有限公司	结合csf-1r的抗体及其用途
CN116715771A (zh) *	2019-12-24	2023-09-08	宝船生物医药科技(上海)有限公司	抗csf1r分子及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
US7993864B2 (en)	2002-12-03	2011-08-09	Ucb Pharma S.A.	Assay for identifying antibody producing cells
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
PL1644412T5 (pl)	2003-07-01	2019-01-31	Ucb Biopharma Sprl	Modyfikowane fragmenty Fab przeciwciała
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) *	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
MY146381A (en) *	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en)	2006-09-29	2006-11-08	Ucb Sa	Altered antibodies
DK2188313T3 (en)	2007-08-21	2017-12-11	Amgen Inc	HUMAN C-FMS ANTI-BINDING PROTEINS
ES2622460T3 (es)	2007-09-26	2017-07-06	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
JO3240B1 (ar) *	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
ES2567298T3 (es)	2008-03-14	2016-04-21	Transgene Sa	Anticuerpo contra el CSF-1R
US8470977B2 (en) *	2008-03-14	2013-06-25	Transgene S.A.	Antibody against the CSF-1R
CA2737241C (en)	2008-09-26	2017-08-29	Ucb Pharma S.A.	Multivalent antibody fusion proteins
ES2667258T3 (es)	2009-09-10	2018-05-10	Ucb Biopharma Sprl	Anticuerpos multivalentes
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
RS58693B1 (sr) *	2009-12-10	2019-06-28	Hoffmann La Roche	Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
EP2542588A1 (en)	2010-03-05	2013-01-09	F. Hoffmann-La Roche AG	Antibodies against human csf-1r and uses thereof
KR101656548B1 (ko)	2010-03-05	2016-09-09	에프. 호프만-라 로슈 아게	인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
AR080698A1 (es) *	2010-04-01	2012-05-02	Imclone Llc	Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
TWI713942B (zh) *	2010-05-04	2020-12-21	美商戊瑞治療有限公司	與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
RU2658603C2 (ru) *	2011-12-15	2018-06-21	Ф.Хоффманн-Ля Рош Аг	Антитела против человеческого csf-1r и их применения
GB201315486D0 (en)	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
GB201315487D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies

2013
- 2013-08-30 GB GBGB1315487.7A patent/GB201315487D0/en not_active Ceased
2014
- 2014-08-05 TW TW103126815A patent/TWI531582B/zh active
- 2014-08-26 AU AU2014314304A patent/AU2014314304B2/en active Active
- 2014-08-26 PE PE2016000313A patent/PE20160528A1/es unknown
- 2014-08-26 MX MX2016002166A patent/MX2016002166A/es active IP Right Grant
- 2014-08-26 EA EA201690503A patent/EA036255B1/ru not_active IP Right Cessation
- 2014-08-26 TN TN2016000067A patent/TN2016000067A1/en unknown
- 2014-08-26 PE PE2020000532A patent/PE20201067A1/es unknown
- 2014-08-26 LT LTEP14755668.2T patent/LT3038643T/lt unknown
- 2014-08-26 FI FIEP19171833.7T patent/FI3549599T3/fi active
- 2014-08-26 UA UAA201601175A patent/UA118354C2/uk unknown
- 2014-08-26 EP EP14755668.2A patent/EP3038643B1/en active Active
- 2014-08-26 RS RS20230962A patent/RS64784B1/sr unknown
- 2014-08-26 SI SI201431235T patent/SI3038643T1/sl unknown
- 2014-08-26 EP EP19171833.7A patent/EP3549599B1/en active Active
- 2014-08-26 RS RS20190833A patent/RS59019B1/sr unknown
- 2014-08-26 CA CA2922240A patent/CA2922240C/en active Active
- 2014-08-26 HR HRP20231264TT patent/HRP20231264T1/hr unknown
- 2014-08-26 DK DK19171833.7T patent/DK3549599T3/da active
- 2014-08-26 PL PL14755668T patent/PL3038643T3/pl unknown
- 2014-08-26 SI SI201432048T patent/SI3549599T1/sl unknown
- 2014-08-26 SG SG11201601151PA patent/SG11201601151PA/en unknown
- 2014-08-26 MA MA44922A patent/MA44922B1/fr unknown
- 2014-08-26 US US14/914,676 patent/US9908939B2/en active Active
- 2014-08-26 MA MA38930A patent/MA38930A1/fr unknown
- 2014-08-26 BR BR112016004324-3A patent/BR112016004324B1/pt active IP Right Grant
- 2014-08-26 LT LTEP19171833.7T patent/LT3549599T/lt unknown
- 2014-08-26 DK DK14755668.2T patent/DK3038643T3/da active
- 2014-08-26 HU HUE19171833A patent/HUE064437T2/hu unknown
- 2014-08-26 PT PT191718337T patent/PT3549599T/pt unknown
- 2014-08-26 HU HUE14755668A patent/HUE045672T2/hu unknown
- 2014-08-26 CN CN202011009068.8A patent/CN112321711A/zh active Pending
- 2014-08-26 ES ES19171833T patent/ES2965207T3/es active Active
- 2014-08-26 KR KR1020167007073A patent/KR102303130B1/ko active IP Right Grant
- 2014-08-26 PL PL19171833.7T patent/PL3549599T3/pl unknown
- 2014-08-26 WO PCT/EP2014/068050 patent/WO2015028455A1/en active Application Filing
- 2014-08-26 MY MYPI2016700624A patent/MY172484A/en unknown
- 2014-08-26 TR TR2019/09478T patent/TR201909478T4/tr unknown
- 2014-08-26 PT PT14755668T patent/PT3038643T/pt unknown
- 2014-08-26 NZ NZ717399A patent/NZ717399A/en unknown
- 2014-08-26 JP JP2016537262A patent/JP6632075B2/ja active Active
- 2014-08-26 ES ES14755668T patent/ES2733735T3/es active Active
- 2014-08-26 EP EP23192221.2A patent/EP4282881A3/en active Pending
- 2014-08-26 CN CN201480057403.8A patent/CN105658236B/zh active Active
- 2014-08-27 AR ARP140103206A patent/AR097464A1/es unknown
- 2014-08-29 UY UY35718A patent/UY35718A/es not_active Application Discontinuation
2016
- 2016-02-09 IL IL244043A patent/IL244043B/en active IP Right Grant
- 2016-02-10 PH PH12016500275A patent/PH12016500275A1/en unknown
- 2016-02-25 CL CL2016000438A patent/CL2016000438A1/es unknown
- 2016-03-02 ZA ZA2016/01437A patent/ZA201601437B/en unknown
- 2016-07-15 HK HK16108335.9A patent/HK1220142A1/zh unknown
2018
- 2018-01-30 US US15/883,130 patent/US10421814B2/en active Active
2019
- 2019-06-12 HR HRP20191051TT patent/HRP20191051T1/hr unknown
- 2019-07-23 CY CY20191100779T patent/CY1121964T1/el unknown
- 2019-09-13 JP JP2019166697A patent/JP7195237B2/ja active Active
2021
- 2021-09-17 JP JP2021152574A patent/JP2022002523A/ja active Pending

Also Published As

Publication number	Publication date
PT3549599T (pt)	2023-11-21
PT3038643T (pt)	2019-07-25
ZA201601437B (en)	2018-08-29
US9908939B2 (en)	2018-03-06
FI3549599T3 (fi)	2023-10-31
IL244043B (en)	2021-01-31
TWI531582B (zh)	2016-05-01
UY35718A (es)	2015-03-27
NZ717399A (en)	2021-12-24
AU2014314304B2 (en)	2019-12-05
TR201909478T4 (tr)	2019-07-22
RS59019B1 (sr)	2019-08-30
LT3038643T (lt)	2019-07-25
CN112321711A (zh)	2021-02-05
JP2016529266A (ja)	2016-09-23
HUE045672T2 (hu)	2020-01-28
ES2965207T3 (es)	2024-04-11
CY1121964T1 (el)	2020-10-14
GB201315487D0 (en)	2013-10-16
DK3038643T3 (da)	2019-06-24
CL2016000438A1 (es)	2016-11-11
MA38930A1 (fr)	2017-12-29
TW201512221A (zh)	2015-04-01
UA118354C2 (uk)	2019-01-10
CA2922240C (en)	2023-09-05
ES2733735T3 (es)	2019-12-02
MA44922A1 (fr)	2019-08-30
SG11201601151PA (en)	2016-03-30
TN2016000067A1 (en)	2017-07-05
HUE064437T2 (hu)	2024-03-28
MA44922B1 (fr)	2020-06-30
IL244043A0 (en)	2016-04-21
JP7195237B2 (ja)	2022-12-23
EP3549599A1 (en)	2019-10-09
US20160200821A1 (en)	2016-07-14
CA2922240A1 (en)	2015-03-05
BR112016004324B1 (pt)	2024-01-16
PL3038643T3 (pl)	2019-11-29
CN105658236A (zh)	2016-06-08
SI3038643T1 (sl)	2019-08-30
EP3038643A1 (en)	2016-07-06
EP4282881A3 (en)	2024-02-21
MX2016002166A (es)	2016-06-23
PE20160528A1 (es)	2016-05-21
KR20160044018A (ko)	2016-04-22
HRP20191051T1 (hr)	2019-09-06
KR102303130B1 (ko)	2021-09-16
DK3549599T3 (en)	2023-10-30
EP3549599B1 (en)	2023-09-06
PH12016500275B1 (en)	2016-05-02
HRP20231264T1 (hr)	2024-02-02
PH12016500275A1 (en)	2016-05-02
PE20201067A1 (es)	2020-10-19
BR112016004324A2 (pt)	2017-10-24
CN105658236B (zh)	2021-03-19
AU2014314304A1 (en)	2016-03-17
SI3549599T1 (sl)	2023-12-29
EA036255B1 (ru)	2020-10-20
JP6632075B2 (ja)	2020-01-15
US20180162947A1 (en)	2018-06-14
JP2022002523A (ja)	2022-01-11
LT3549599T (lt)	2023-11-10
MY172484A (en)	2019-11-26
PL3549599T3 (pl)	2024-03-04
RS64784B1 (sr)	2023-11-30
US10421814B2 (en)	2019-09-24
WO2015028455A1 (en)	2015-03-05
EP4282881A2 (en)	2023-11-29
AR097464A1 (es)	2016-03-16
JP2020005652A (ja)	2020-01-16
EP3038643B1 (en)	2019-05-01
EA201690503A1 (ru)	2016-06-30

Publication	Publication Date	Title
IL269528A (en)	2019-11-28	Anti- FCRH5 antibodies
HRP20190502T1 (hr)	2019-05-03	Afukozilirana anti-fgfr2iiib protutijela
HK1217023A1 (zh)	2016-12-16	新型抗體
GB201322583D0 (en)	2014-02-05	Antibodies
HK1220142A1 (zh)	2017-04-28	抗體
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
GB201300706D0 (en)	2013-02-27	Antibody
IL245488A0 (en)	2016-06-30	Anti- ccl17 antibodies
GB201312226D0 (en)	2013-08-21	Improved antibodies
HK1220763A1 (zh)	2017-05-12	免疫試驗
GB201318283D0 (en)	2013-11-27	Antibodies